vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2020-1-40-49vtio-1142Research ArticleКлиническая трансплантологияClinical TransplantologyВозрастные особенности субпопуляционного состава лимфоцитов и функциональной активности мононуклеаров периферической крови у больных хронической болезнью почек до и после трансплантацииAge-related features of the pattern of lymphocyte subpopulations and functional activity of peripheral blood mononuclear cells in patients with chronic kidney disease before and after transplantationАртемовД. В.ArtemovD. V.

Артемов Дмитрий Владимирович.

129110, Москва, ул. Щепкина, д. 61/2, корпус 6.

Artemov Dmitriy Vladimirovich.

Building 6, 61/2, Shchepkina str., Moscow, 129110

anatom555@yandex.ruЗулькарнаевА. Б.ZulkarnaevA. B.

Москва

Moscow

ВатазинА. В.VatazinA. V.

Москва

Moscow

ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»РоссияM.F. Vladimirsky Moscow Regional Clinical and Research InstituteRussian Federation2020210420202214049Copyright © Артемов Д.В., Зулькарнаев А.Б., Ватазин А.В., 20202020Артемов Д.В., Зулькарнаев А.Б., Ватазин А.В.Artemov D.V., Zulkarnaev A.B., Vatazin A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1142хроническая болезнь почектрансплантация почкисубпопуляции лимфоцитовфункциональная активность клетокchronic kidney diseasekidney transplantationlymphocyte subpopulationscell functional activityReferencesUSRDS.org [Internet]. United States Renal Data System. 2016 USRDS annual data report. Volume 2 – End-stage Renal Disease (ESRD) in the United States: 1 · Incidence, Prevalence, Patient Characteristics, and Treatment Modalities 2016; Available at: https://www. usrds.org/2016/view/Default.aspx.USRDS.org [Internet]. United States Renal Data System. 2016 USRDS annual data report. Volume 2 – End-stage Renal Disease (ESRD) in the United States: 1 · Incidence, Prevalence, Patient Characteristics, and Treatment Modalities 2016; Available at: https://www. usrds.org/2016/view/Default.aspx.Томилина НА, Андрусев АМ, Перегудова НГ, Шинкарев МБ. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации В 2010–2015 гг. Отчет по данным общероссийского регистра заместительной почечной терапии Российского диализного общества, часть первая. Нефрология и диализ. 2017; 19 (4, приложение): 1–95. doi: 10.28996/1680-4422-2017-4suppl-1-95.Tomilina NA, Andrusev AM, Peregudova NG, Shinkarev MB. Renal replacement therapy for End Stage Renal Disease in Russian Federation, 2010–2015. Russian National Renal Replacement Therapy Registry Report of Russian Public Organization of Nephrologists «Russian Dialysis Society», Part 1. Nefrologiya i dializ [Nephrology and dialysis]. 2017; 19 (4, supplement): 1–95. [In Russ, English abstract]. doi: 10.28996/1680-4422-2017-4suppl-1-95.ERA-EDTA-reg.org [Internet]. European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015. 2017; Available at: https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2015.pdf.ERA-EDTA-reg.org [Internet]. European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015. 2017; Available at: https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2015.pdf.Chopra B, Sureshkumar KK. Changing organ allocation policy for kidney transplantation in the United States. World J Transplant. 2015; 5 (2): 38–43. doi: 10.5500/wjt.v5.i2.38.Chopra B, Sureshkumar KK. Changing organ allocation policy for kidney transplantation in the United States. World J Transplant. 2015; 5 (2): 38–43. doi: 10.5500/wjt.v5.i2.38.Нестеренко ИВ, Ватазин АВ, Филипцев ПЯ, Янковой АГ. Новый подход в оценке почечных трансплантатов, полученных от возрастных маргинальных доноров. Медицинский альманах. 2008; 5: 23–24.Nesterenko IV, Vatazin AV, Filiptsev PYa, Yankovoi AG. The new approach to kidney trasplants having got from aged marginal donors. Meditsinskii al’manakh. 2008; 5: 23–24. [In Russian].Нестеренко ИВ, Ватазин АВ, Филипцев ПЯ, Янковой АГ. Трансплантация почки от маргинальных доноров, получающих в процессе кондиционирования высокие дозы инотропной поддержки. Медицинский альманах. 2008; 5: 25–27.Nesterenko IV, Vatazin AV, Filiptsev PYa, Yankovoi AG. The kidney transplantation from marginal donors getting high doses of inotropic support while conditioning process. Meditsinskii al’manakh. 2008; 5: 25–27. [In Russian].Нестеренко ИВ, Филипцев ПЯ, Ватазин АВ. Новые аспекты использования маргинальных доноров с сопутствующими заболеваниями. Альманах клинической медицины. 2008; 18: 29–34.Nesterenko IV, Filiptsev PYa, Vatazin AV. New aspects of using marginal donors with concomitant diseases. Al’manakh klinicheskoi meditsiny. 2008; 18: 29–34. [In Russian].Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? Drugs Aging. 2001; 18 (10): 751–759. doi: 10.2165/00002512-200118100-00004.Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? Drugs Aging. 2001; 18 (10): 751–759. doi: 10.2165/00002512-200118100-00004.Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int. 2001; 59 (4): 1539– 1543. doi: 10.1046/j.1523-1755.2001.0590041539.x.Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int. 2001; 59 (4): 1539– 1543. doi: 10.1046/j.1523-1755.2001.0590041539.x.de Fijter JW. The impact of age on rejection in kidney transplantation. Drugs Aging. 2005; 22 (5): 433–449. doi: 10.2165/00002512-200522050-00007.de Fijter JW. The impact of age on rejection in kidney transplantation. Drugs Aging. 2005; 22 (5): 433–449. doi: 10.2165/00002512-200522050-00007.Danovitch GM., Gill J, Bunnapradist S. Immunosuppression of the elderly kidney transplant recipient. Transplantation. 2007; 84 (3): 285–291. doi: 10.1097/01.tp.0000275423.69689.dc.Danovitch GM., Gill J, Bunnapradist S. Immunosuppression of the elderly kidney transplant recipient. Transplantation. 2007; 84 (3): 285–291. doi: 10.1097/01.tp.0000275423.69689.dc.Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237–248.Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237–248.Singh P, Ng YH, Unruh M. Kidney Transplantation Among the Elderly: Challenges and Opportunities to Improve Outcomes. Adv Chronic Kidney Dis. 2016; 23 (1): 44–50. doi: 10.1053/j.ackd.2015.11.002.Singh P, Ng YH, Unruh M. Kidney Transplantation Among the Elderly: Challenges and Opportunities to Improve Outcomes. Adv Chronic Kidney Dis. 2016; 23 (1): 44–50. doi: 10.1053/j.ackd.2015.11.002.Nikodimopoulou M, Karakasi K, Daoudaki M, Fouza A, Vagiotas L, Myserlis G et al. Kidney Transplantation in Old Recipients From Old Donors: A Single-Center Experience. Transplant Proc. 2019; 51 (2): 405–407. doi: 10.1016/j.transproceed.2019.01.019.Nikodimopoulou M, Karakasi K, Daoudaki M, Fouza A, Vagiotas L, Myserlis G et al. Kidney Transplantation in Old Recipients From Old Donors: A Single-Center Experience. Transplant Proc. 2019; 51 (2): 405–407. doi: 10.1016/j.transproceed.2019.01.019.Geraci PM, Sepe V. Non-heart-beating organ donation in Italy. Minerva Anestesiol. 2011; 77 (6): 613–623.Geraci PM, Sepe V. Non-heart-beating organ donation in Italy. Minerva Anestesiol. 2011; 77 (6): 613–623.Трансплантология. 2-е изд., испр. и доп. Под ред. В.И. Шумакова. М.: МИА, 2006.Transplantology. 2nd edition. V.I. Shumakov, ed. Moscow: MIA, 2006. (In Russ.).Трансплантология. Фармакотерапия без ошибок. Под ред. С.В. Готье, Я.Г. Мойсюка. М.: Е-ното, 2014: 122–179.Transplantology. Pharmacotherapy without mistakes. S.V. Gautier, Ya.G. Moisyuk, eds. Moscow: E-noto, 2014: 122–179. (In Russian).Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014; 60 (2): 130–137. doi: 10.1159/000355303.Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014; 60 (2): 130–137. doi: 10.1159/000355303.Valdiglesias V, Sánchez-Flores M, Maseda A, Marcos-Pérez D, Millán-Calenti JC, Pásaro E et al. Lymphocyte Subsets in a Population of Nonfrail Elderly Individuals. J Toxicol Environ Health A. 2015; 78 (13–14): 790–804. doi: 10.1080/15287394.2015.1051170.Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014; 60 (2): 130–137. doi: 10.1159/000355303.Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D et al. Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016; 46 (10): 2286–2301. doi: 10.1002/eji.201546178.Valdiglesias V, Sánchez-Flores M, Maseda A, Marcos-Pérez D, Millán-Calenti JC, Pásaro E et al. Lymphocyte Subsets in a Population of Nonfrail Elderly Individuals. J Toxicol Environ Health A. 2015; 78 (13–14): 790–804. doi: 10.1080/15287394.2015.1051170.Gill Z, Nieuwoudt M, Ndifon W. The Hayflick Limit and Age-Related Adaptive Immune Deficiency. Gerontology. 2018; 64 (2): 135–139. doi: 10.1159/000478091.Valdiglesias V, Sánchez-Flores M, Maseda A, Marcos-Pérez D, Millán-Calenti JC, Pásaro E et al. Lymphocyte Subsets in a Population of Nonfrail Elderly Individuals. J Toxicol Environ Health A. 2015; 78 (13–14): 790–804. doi: 10.1080/15287394.2015.1051170.Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9 (5): 255–265. doi: 10.1038/nrneph.2013.44.Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D et al. Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016; 46 (10): 2286–2301. doi: 10.1002/eji.201546178.Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015; 30 (6): 1028–1037. doi: 10.1093/ndt/gfv007.Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D et al. Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016; 46 (10): 2286–2301. doi: 10.1002/eji.201546178.Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015; 26 (10): 2512– 2520. doi: 10.1681/ASN.2014101034.Gill Z, Nieuwoudt M, Ndifon W. The Hayflick Limit and Age-Related Adaptive Immune Deficiency. Gerontology. 2018; 64 (2): 135–139. doi: 10.1159/000478091.Cheung CY, Chan GC, Chan SK, Ng F, Lam MF, Wong SS et al. Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study. Am J Nephrol. 2016; 43 (3): 153–159. doi: 10.1159/000445362.Gill Z, Nieuwoudt M, Ndifon W. The Hayflick Limit and Age-Related Adaptive Immune Deficiency. Gerontology. 2018; 64 (2): 135–139. doi: 10.1159/000478091.Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008; 19 (8): 1483–1490. doi: 10.1681/ASN.2007090971.Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9 (5): 255–265. doi: 10.1038/nrneph.2013.44.Kim JU, Kim M, Kim S, Nguyen TT, Kim E, Lee S, Kim S, Kim H. Dendritic Cell Dysfunction in Patients with Endstage Renal Disease. Immune Netw. 2017; 17 (3): 152– 162. doi: 10.4110/in.2017.17.3.152.Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9 (5): 255–265. doi: 10.1038/nrneph.2013.44.Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006; 118 (1): 83–91. doi: 10.1016/j.clim.2005.09.007.Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015; 30 (6): 1028–1037. doi: 10.1093/ndt/gfv007.Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006; 70 (2): 371–376. doi: 10.1038/sj.ki.5001550.Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015; 30 (6): 1028–1037. doi: 10.1093/ndt/gfv007.Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 2011; 80 (2): 208–217. doi: 10.1038/ki.2011.110.Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015; 26 (10): 2512– 2520. doi: 10.1681/ASN.2014101034.Lisowska KA, Dębska-Ślizień A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2012; 32 (1): 189–200. doi: 10.1007/s10875-011-9603-x.Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015; 26 (10): 2512– 2520. doi: 10.1681/ASN.2014101034.Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014; 27 (12): 1272–1284. doi: 10.1111/tri.12416.Cheung CY, Chan GC, Chan SK, Ng F, Lam MF, Wong SS et al. Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study. Am J Nephrol. 2016; 43 (3): 153–159. doi: 10.1159/000445362.Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13 (1): 204–212.Cheung CY, Chan GC, Chan SK, Ng F, Lam MF, Wong SS et al. Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study. Am J Nephrol. 2016; 43 (3): 153–159. doi: 10.1159/000445362.Xie DQ, Gan H, Du XG, Li ZR, Wu J. The characterization of Th1/Th2 profile in end-stage renal disease patients and the correlation with the apoptosis of T lymphocyte. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006; 22 (6): 763–766.Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008; 19 (8): 1483–1490. doi: 10.1681/ASN.2007090971.Winterberg PD, Ford ML. The effect of chronic kidney disease on T cell alloimmunity. Curr Opin Organ Transplant. 2017; 22 (1): 22–28. doi: 10.1097/MOT.0000000000000375.Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008; 19 (8): 1483–1490. doi: 10.1681/ASN.2007090971.Lisowska KA, Debska-Slizien A, Radzka M, Witkowski JM, Rutkowski B, Bryl E. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4- positive T lymphocytes. Artif Organs. 2010; 34 (3): E77–84. doi: 10.1111/j.1525-1594.2009.00942.x.Kim JU, Kim M, Kim S, Nguyen TT, Kim E, Lee S, Kim S, Kim H. Dendritic Cell Dysfunction in Patients with Endstage Renal Disease. Immune Netw. 2017; 17 (3): 152– 162. doi: 10.4110/in.2017.17.3.152.Betjes MG, Litjens NH. Chronic kidney disease and premature ageing of the adaptive immune response. Curr Urol Rep. 2015; 16 (1): 471. doi: 10.1007/s11934-014-0471-9.Kim JU, Kim M, Kim S, Nguyen TT, Kim E, Lee S, Kim S, Kim H. Dendritic Cell Dysfunction in Patients with Endstage Renal Disease. Immune Netw. 2017; 17 (3): 152– 162. doi: 10.4110/in.2017.17.3.152.Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol. 2007; 18 (5): 1602–1606. doi: 10.1681/ASN.2006101105.Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006; 118 (1): 83–91. doi: 10.1016/j.clim.2005.09.007.Crespo E, Lucia M, Cruzado JM, Luque S, Melilli E, Manonelles A et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving Tcell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618. doi: 10.1371/journal.pone.0117618.Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006; 118 (1): 83–91. doi: 10.1016/j.clim.2005.09.007.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006; 70 (2): 371–376. doi: 10.1038/sj.ki.5001550.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006; 70 (2): 371–376. doi: 10.1038/sj.ki.5001550.Ватазин АВ, Зулькарнаев АБ, Степанов ВА. Анализ выживаемости пациентов в листе ожидания трансплантации почки с позиции конкурирующих рисков. Вестник трансплантологии и искусственных органов. 2019; 21 (1): 35–45. doi: 10.15825/1995-1191-2019-1-35-45.Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 2011; 80 (2): 208–217. doi: 10.1038/ki.2011.110.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 2011; 80 (2): 208–217. doi: 10.1038/ki.2011.110.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 2011; 80 (2): 208–217. doi: 10.1038/ki.2011.110.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Lisowska KA, Dębska-Ślizień A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2012; 32 (1): 189–200. doi: 10.1007/s10875-011-9603-x.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Lisowska KA, Dębska-Ślizień A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2012; 32 (1): 189–200. doi: 10.1007/s10875-011-9603-x.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Lisowska KA, Dębska-Ślizień A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2012; 32 (1): 189–200. doi: 10.1007/s10875-011-9603-x.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014; 27 (12): 1272–1284. doi: 10.1111/tri.12416.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014; 27 (12): 1272–1284. doi: 10.1111/tri.12416.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014; 27 (12): 1272–1284. doi: 10.1111/tri.12416.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13 (1): 204–212.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13 (1): 204–212.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13 (1): 204–212.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Xie DQ, Gan H, Du XG, Li ZR, Wu J. The characterization of Th1/Th2 profile in end-stage renal disease patients and the correlation with the apoptosis of T lymphocyte. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006; 22 (6): 763–766.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Xie DQ, Gan H, Du XG, Li ZR, Wu J. The characterization of Th1/Th2 profile in end-stage renal disease patients and the correlation with the apoptosis of T lymphocyte. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006; 22 (6): 763–766.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Xie DQ, Gan H, Du XG, Li ZR, Wu J. The characterization of Th1/Th2 profile in end-stage renal disease patients and the correlation with the apoptosis of T lymphocyte. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006; 22 (6): 763–766.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Winterberg PD, Ford ML. The effect of chronic kidney disease on T cell alloimmunity. Curr Opin Organ Transplant. 2017; 22 (1): 22–28. doi: 10.1097/MOT.0000000000000375.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Winterberg PD, Ford ML. The effect of chronic kidney disease on T cell alloimmunity. Curr Opin Organ Transplant. 2017; 22 (1): 22–28. doi: 10.1097/MOT.0000000000000375.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Winterberg PD, Ford ML. The effect of chronic kidney disease on T cell alloimmunity. Curr Opin Organ Transplant. 2017; 22 (1): 22–28. doi: 10.1097/MOT.0000000000000375.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Lisowska KA, Debska-Slizien A, Radzka M, Witkowski JM, Rutkowski B, Bryl E. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4- positive T lymphocytes. Artif Organs. 2010; 34 (3): E77–84. doi: 10.1111/j.1525-1594.2009.00942.x.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Lisowska KA, Debska-Slizien A, Radzka M, Witkowski JM, Rutkowski B, Bryl E. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4- positive T lymphocytes. Artif Organs. 2010; 34 (3): E77–84. doi: 10.1111/j.1525-1594.2009.00942.x.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Lisowska KA, Debska-Slizien A, Radzka M, Witkowski JM, Rutkowski B, Bryl E. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4- positive T lymphocytes. Artif Organs. 2010; 34 (3): E77–84. doi: 10.1111/j.1525-1594.2009.00942.x.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Betjes MG, Litjens NH. Chronic kidney disease and premature ageing of the adaptive immune response. Curr Urol Rep. 2015; 16 (1): 471. doi: 10.1007/s11934-014-0471-9.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Betjes MG, Litjens NH. Chronic kidney disease and premature ageing of the adaptive immune response. Curr Urol Rep. 2015; 16 (1): 471. doi: 10.1007/s11934-014-0471-9.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Betjes MG, Litjens NH. Chronic kidney disease and premature ageing of the adaptive immune response. Curr Urol Rep. 2015; 16 (1): 471. doi: 10.1007/s11934-014-0471-9.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol. 173.6.3716.Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol. 2007; 18 (5): 1602–1606. doi: 10.1681/ASN.2006101105.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol. 2007; 18 (5): 1602–1606. doi: 10.1681/ASN.2006101105.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol. 2007; 18 (5): 1602–1606. doi: 10.1681/ASN.2006101105.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Crespo E, Lucia M, Cruzado JM, Luque S, Melilli E, Manonelles A et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving Tcell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618. doi: 10.1371/journal.pone.0117618.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Crespo E, Lucia M, Cruzado JM, Luque S, Melilli E, Manonelles A et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving Tcell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618. doi: 10.1371/journal.pone.0117618.Crespo E, Lucia M, Cruzado JM, Luque S, Melilli E, Manonelles A et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving Tcell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618. doi: 10.1371/journal.pone.0117618.Crespo E, Lucia M, Cruzado JM, Luque S, Melilli E, Manonelles A et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving Tcell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618. doi: 10.1371/journal.pone.0117618.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Hart A, Salkowski N, Snyder JJ, Israni AK, Kasiske BL. Beyond «Median Waiting Time»: Development and Validation of a Competing Risk Model to Predict Outcomes on the Kidney Transplant Waiting List. Transplantation. 2016; 100 (7): 1564–1570. doi: 10.1097/TP.0000000000001185.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Gritane K, Jusinskis J, Malcevs A, Suhorukovs V, Amerika D, Puide I et al. Influence of Pretransplant Dialysis Vintage on Repeated Kidney Transplantation Outcomes. Transplant Proc. 2018; 50 (5): 1249–1257. doi: 10.1016/j.transproceed.2018.01.056.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 35–45. [In Russ, English abstract]. doi: 10.15825/1995-1191-2019-1-35-45.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15 (4): 1028–1038. doi: 10.1111/ajt.13092.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Luque Y, Jamme M, Rabant M, DeWolf S, Noël LH, Thervet E et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016; 31 (3): 487–495. doi: 10.1093/ndt/gfv362.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016; 16 (5): 310–320. doi: 10.1038/nri.2016.34.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9: 1869. doi: 10.3389/fimmu.2018.01869.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016; 38 (1): 7–14. doi: 10.3109/0886022X.2015.1106871.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Schmaderer C, Heemann U. Blocking innate immunity to slow the progression of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 905–907. doi: 10.1007/s00210-014-1031-z.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata- Ortiz P, Bragado R et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015; 97 (3): 583–598. doi: 10.1189/jlb.4A0714-326R.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Law BMP, Wilkinson R, Wang X, Kildey K, Lindner M, Rist MJ et al. Interferon-γ production by tubulointerstitial human CD56 bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017; 92 (1): 79–88. doi: 10.1016/j.kint.2017.02.006.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Turner JE. Natural killers: the bad guys in fibrosis? Kidney Int. 2017; 92 (1): 9–11. doi: 10.1016/j.kint.2017.03.011.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Hamze M, Desmetz C, Guglielmi P. B cell-derived cytokines in disease. Eur Cytokine Netw. 2013; 24 (1): 20–26. doi: 10.1684/ecn.2013.0327.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12 (6): 983–997. doi: 10.2215/CJN.11761116.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia. 2017; 37 (5): 465–477. doi: 10.1016/j.nefro.2017.03.012.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Kattah AG, Fervenza FC, Roccatello D. Rituximabbased novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013; 12 (8): 854–859. doi: 10.1016/j.autrev.2012.09.002.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010; 25 (1): 205–212. doi: 10.1093/ndt/gfp397.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44 (8): 465–472. doi: 10.3858/emm.2012.44.8.053.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Malinowski K, Tsukuda K, Terashima T, Rapaport FT. Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Transplant Proc. 1997; 29 (1–2): 1020–1024.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Naicker SD, Cormican S, Griffin TP, Maretto S, Martin WP, Ferguson JP et al. Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Front Immunol. 2018; 9: 2845. doi: 10.3389/fimmu.2018.02845.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Shimaoka M, Hosotsubo K, Sugimoto M, Sakaue G, Taenaka N, Yoshiya I et al. The influence of surgical stress on T cells: enhancement of early phase lymphocyte activation. Anesth Analg. 1998; 87 (6): 1431–1435.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Buunen M, Gholghesaei M, Veldkamp R, Meijer DW, Bonjer HJ, Bouvy ND. Stress response to laparoscopic surgery: a review. Surg Endosc. 2004; 18 (7): 1022– 1028. doi: 10.1007/s00464-003-9169-7.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Bartal I, Melamed R, Greenfeld K, Atzil S, Glasner A, Domankevich V et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010; 24 (3): 376–386. doi: 10.1016/j.bbi.2009.02.010.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Caprara GV, Nisini R, Castellani V, Vittorio P, Alessandri G, Vincenzo Z et al. Lymphocyte subsets are influenced by positivity levels in healthy subjects before and after mild acute stress. Immunol Lett. 2017; 188: 13–20. doi: 10.1016/j.imlet.2017.05.012.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349 (24): 2326–2333. doi: 10.1056/NEJMoa020009.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004; 5 (12): 1260–1265. doi: 10.1038/ni1138.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173 (6): 3716–3724. doi: 10.4049/jimmunol.173.6.3716.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cellmediated graft-versus-host disease. J Immunol. 2010; 184 (12): 6790–6798. doi: 10.4049/jimmunol.0902598.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010; 184 (12): 6649–6657. doi: 10.4049/jimmunol.0903729.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor- derived dendritic cells favor indirect alloreactivity. J Immunol. 2010; 184 (5): 2329–2336. doi: 10.4049/jimmunol.0902748.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.Meier-Kriesche H, Ojo AO, Arndorfer JA, Leichtman AB, Lake K, Cibrik DM et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc. 2001; 33 (1–2): 1190–1191. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12 (12): 3326–3336. doi: 10.1111/j.1600-6143.2012.04232.x.

The authors declare that there are no conflicts of interest present.